Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

A-095

Supelco

Atomoxetine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C17H22ClNO
Numéro CAS:
82248-59-7
Poids moléculaire :
291.82
Numéro CE :
200-659-6
Numéro MDL:
MFCD06410992
Code UNSPSC :
41116107
ID de substance PubChem :
329770640
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol (as free base)

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

forensics and toxicology

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

Cl.CNCC[C@@H](Oc1ccccc1C)c2ccccc2

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

Clé InChI

LUCXVPAZUDVVBT-UNTBIKODSA-N

Informations sur le gène

human ... SLC6A2(6530)

Description générale

Atomoxetine is an attention-deficit hyperactivity disorder (ADHD) drug marketed in the US under the trade name Strattera®. This Certified Spiking Solution® is suitable for use in numerous testing applications such as clinical toxicology, forensic analysis, pharmaceutical research, urine drug testing, or calibrator preparation.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Strattera is a registered trademark of Eli Lilly and Co.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Adriana Alexandre dos Santos Tavares et al.
Synapse (New York, N.Y.), 67(1), 30-41 (2012-10-09)
This study aims to investigate the pharmacokinetics of a recently developed radiotracer for imaging of the norepinephrine transporter (NET) in baboon brain, (123)I-INER, using single photon emission computed tomography (SPECT). In addition, it also aims to determine NET occupancy by
Chi-Yung Shang et al.
Journal of child and adolescent psychopharmacology, 22(5), 353-363 (2012-10-23)
Atomoxetine is efficacious in reducing symptoms of attention- deficit/hyperactivity disorder (ADHD), but its effect on visual memory and attention needs more investigation. This study aimed to assess the effect of atomoxetine on visual memory, attention, and school function in boys
Emilia Marchei et al.
Drug testing and analysis, 5(3), 191-195 (2012-09-20)
Atomoxetine (ATX) is a selective norepinephrine reuptake inhibitor approved since 2002 for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults as an alternative treatment to methylphenidate. Within the framework of a project evaluating the use
Michael Turner et al.
Behavioural brain research, 243, 28-37 (2012-12-26)
Atomoxetine (ATX) is a commonly used non-stimulant treatment for Attention deficit hyperactivity disorder (ADHD). It primarily acts to increase noradrenalin levels; however, at higher doses it can increase dopamine levels. To date there has been no investigations into the effects
Hedi Schelleman et al.
PloS one, 8(1), e52991-e52991 (2013-02-06)
To compare the incidence rates of serious cardiovascular events in adult initiators of amphetamines or atomoxetine to rates in non-users. This was a retrospective cohort study of new amphetamines (n=38,586) or atomoxetine (n=20,995) users. Each medication user was matched to
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique